Information  X 
Enter a valid email address

Valereum Blockchain (VLRM)


Monday 26 April, 2021

Valereum Blockchain

Notice of Exercise of Warrants

RNS Number : 5828W
Valereum Blockchain PLC
26 April 2021

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”)

26 April 2021

Valereum Blockchain Plc

("Valereum" or the "Company")


Notice of Exercise of Warrants

Valereum Blockchain Plc (AQSE: VLRM), the blockchain technology venture builder, has received an exercise notice of warrants for 625,000 new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") with an exercise price of 0.4 pence each. The exercise consideration is £25,000.

Application will be made for the Ordinary Shares to be admitted to trading on AQSE Growth Market and dealings are expected to commence on or around 30 April 2021.

Following the admission of the Ordinary Shares, the Company's total issued and voting share capital will comprise of 64,669,882 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, securities of the Company.

The Directors of the Company accept responsibility for the contents of this announcement.



The website address of the Company is .


Valereum Blockchain Plc

Richard Poulden, Chairman

Tel: +44 7551 863830


AQSE Growth Market Corporate Adviser

Peterhouse Capital Limited

Guy Miller / Allie Feuerlein

Tel: +44 (0) 207 469 0930


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t